NEW YORK, Feb. 24 /PRNewswire/ -- Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher’s disease, Fabry’s disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease.
“Despite being a broad product area with over $2 billion in annual sales, it has been nearly impossible to systematically track the genetic disorder market, especially on a global basis,” said Maxim Jacobs, Senior Analyst at Guidepoint Global. “This need has become even more acute with the recent supply disruptions in Gaucher’s and Fabry’s as well as the upcoming new product launches. Guidepoint Global’s new Genetic Disorder Tracker will provide followers of the genetic disorder market with a much needed tool to analyze the market and identify meaningful changes in the size and character of the commercial landscape.”
An overview of Guidepoint Global’s proprietary suite of Tracker offerings is available at http://www.guidepointglobal.com.
Guidepoint Global is a leading primary research firm founded in 2003 providing customized information solutions in the Healthcare, Technology, Media, Telecommunications, Energy, Industrials, Consumer Goods & Services, and Financial Services sectors. Clients include some of the world’s leading private equity firms, mutual funds, hedge funds, strategy consultancies and multinational companies. Through phone consultations, face-to-face meetings, custom surveys, and proprietary data products, coupled with an industry-leading compliance platform, Guidepoint provides its clients with the insight required to make informed decisions.
CONTACT: Zachary Wills, Vice President, Tracker Sales of Guidepoint
Global, +1-646-395-9344, zwills@guidepointglobal.com
Web site: http://www.guidepointglobal.com/
